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Abstract  
Conflicting evidence exist about the effects of angiotensin-converting enzyme inhibitors 
(ACEIs)/angiotensin-receptor blockers (ARBs) on COVID-19 clinical outcomes. We aimed to provide a 
comprehensive/updated evaluation of the effect of ACEIs/ARBs on COVID-19 related-clinical outcomes, 
including exploration of inter-class differences between ACEIs and ARBs, using a systematic review/meta-
analysis approach conducted in Medline (OVID), Embase, Scopus, Cochrane library and medRxiv from 
inception to 22nd May 2020. English studies that evaluated the effect of ACEIs/ARBs among patients with 
COVID-19 were included. Studies’ quality was appraised using the Newcastle-Ottawa Scale. Data were 
analysed using the random-effects modelling stratified by exposure (ACEIs/ARBs, ACEIs, and ARBs). 
Heterogenicity was assessed using I2 statistic. Several sub-group analyses were conducted to explore the 
impact of potential confounders. Overall, 27 studies were eligible. The pooled analyses showed non-
significant associations between ACEIs/ARBs and death (OR:0.97, 95%CI:0.75,1.27), ICU admission 
(OR:1.09;95%CI:0.65,1.81), death/ICU admission (OR:0.67; 95%CI:0.52,0.86), risk of COVID-19 infection 
(OR:1.01; 95%CI:0.93,1.10), severe infection (OR:0.78; 95%CI:0.53,1.15) and hospitalisation (OR:1.15; 
95%CI:0.81,1.65). However, the sub-group analyses indicated significant association between 
ACEIs/ARBs and hospitalisation among USA studies (OR:1.59; 95%CI:1.03,2.44), peer-reviewed 
(OR:1.93, 95%CI:1.38,2.71), good quality and studies which reported adjusted measure of effect (OR:1.30, 
95%CI:1.10,1.50). Significant differences were found between ACEIs and ARBs with the latter being 
significantly associated with lower risk of acquiring COVID-19 infection (OR:0.24; 95%CI: 0.17,0.34). In 
conclusion, high-quality evidence exist for the effect of ACEIs/ARBs on some COVID-19 clinical outcomes. 
For the first time, we provided evidence, albeit of low quality, on inter-class differences between ACEIs and 
ARBs for some of the reported clinical outcome.  
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Introduction  1 
Soon after the report of first clusters of COVID-19 cases in China in December 2019, concerns were raised 2 
among clinicians and investigators that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-3 
receptor blockers (ARBs) might increase susceptibility to COVID-19 infection and the likelihood of severe 4 
and fatal COVID-19 illness [1]. These concerns are based on the concept that angiotensin-converting 5 
enzyme 2 (ACE2), an enzyme potentially up-regulated by ACEIs/ARBs use, is the viral entry receptor that 6 
COVID-19 uses to enter lung cell [2], coupled with the observation of high prevalence of hypertension and 7 
other cardiovascular comorbidities among COVID-19 patients who have poor outcomes [3] . Consequently, 8 
it was speculated that due to considerable prescribing of ACEIs/ARBs to treat cardiovascular diseases 9 
(CVD), this would adversely affect outcomes from COVID-19 [4] with underlying cardiac and kidney 10 
diseases already associated with poorer outcomes [3,5,6]. Consequently, care to avoid treatments that well 11 
add to this. 12 
 13 
Unsurprisingly, discussions regarding the potential impact of ACEIs/ ARBs has resulted in anxiety, which 14 
might cause patients and clinicians to discontinue or stop these medications [7] . This should be avoided 15 
as there will be harm from the indiscriminate withdrawal of ACEIs/ARBs [8]. This concern is complicated by 16 
uncertainty surrounding the up-regulation of ACE2 by ACEIs/ARBs [9]. Furthermore, the paradoxical 17 
protective role of ACEIs/ARBs in COVID-19 patients is also being proposed [10]. Due to these controversial 18 
findings, and despite consistent and reassuring recommendations for the continued use of ACEIs/ARBs in 19 
COVID-19 patients issued by International Societies [11], these concerns remain. We wish to address this 20 
as we have already seen the impact that inappropriate endorsement of treatments can have on morbidity 21 
and mortality. Early endorsement of hydroxychloroquine resulted in drug shortages for other indications, 22 
price hikes, increased adverse drug reactions and deaths from suicides [12,13]. However, subsequent 23 
studies failed to show clinical benefit resulting in the World Health Organisation (WHO) and the National 24 
Institute of Health (NIH) in the USA stopping the hydroxychloroquine arm in their studies [14-16]. A similar 25 
situation has been seen with lopinavir/ritonavir[15]. Consequently it is imperative that any considerations 26 
regarding management are evidenced based. 27 
 28 
We are aware that several observational studies have been conducted to address these concerns. 29 
However, these studies have reported conflicting findings which is a concern given the controversies with 30 
hydroxychloroquine and lopinavir/ritonavir. For instance, some studies [17-22] have reported a lower risk 31 
of severe COVID-19 outcomes with ACEIs/ARBs whilst another study [23] found a higher risk. Similarly, 32 
ACEIs/ARBs have been associated with lower mortality rates in some studies [17,20,24-27] whilst others 33 
[23,28] reported higher mortality rates. We are also aware that two recently published systematic reviews 34 
[29,30] containing 16 studies reported no evidence of any association between ACEIs/ARBs and mortality, 35 
severe COVID-19 outcomes, or acquiring COVID-19 infection; however, these studies only analysed a 36 
limited range of outcomes, and did not report the effects of ACEIs and ARBs individually. The authors also 37 
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did not undertake any sub-group analysis to explore the effect of potential confounders such as study’s 38 
quality and there are concerns that the findings may now be out-dated. Furthermore, one of these studies 39 
[30] only used narrative synthesis of the data. Consequently, we sought to undertake an updated and 40 
comprehensive evaluation of effect of ACEIs/ARBs use on all reported COVID-19 related outcomes, 41 
including exploration of any class differences, through a systematic review of the literature coupled with a 42 
meta-analysis. 43 
 44 
Methods  45 
Data Source and Searches 46 
This systematic review and meta-analysis was conducted and reported in accordance to the Preferred 47 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement checklist [32]. A protocol 48 
was drafted and shared with authors but not registered in any database as we did not want the submission 49 
of our findings be delayed until the study protocol was registered as we wanted to provide the clinical 50 
community with a timely publication of the available evidence whether published in peer-reviewed journals 51 
or awaiting publication surrounding the impact of ACEIs/ARBs use on COVID-19 outcomes. The literature 52 
search was conducted in Embase, Medline (OVID), Scopus, Cochrane library and medRxiv, from inception 53 
to 22nd May 2020, using key terms related to ACEIs/ARBs and COVID-19 concepts. A detailed electronic 54 
search strategy used in the database searches is attached [Supplementary file 1]. We also manually 55 
searched the reference list of eligible articles to identify any further relevant articles.  56 
 57 
Study Selection 58 
Eligibility criteria included original research studies, published in English, with COVID-19 patients (target 59 
population) that reported the effects of ACEIs/ARBs (intervention), in comparison with non ACEIs/ARBs 60 
use (comparison), on COVID-19 related outcomes. No restrictions were placed on the reported outcomes 61 
or study types. All records identified from the search strategy were exported from the databases and 62 
imported into Covidence® [31] whereby duplicate records were removed. Two reviewers (NA and LA) 63 
independently undertook titles and abstract screening for relevance, followed by selecting records for full-64 
text screening and data extraction. At each stage, discrepancies were resolved through discussion until 65 
consensus was achieved. A third author (AK) verified the eligibility of the included studies. 66 
 67 
Data Extraction and Quality Assessment 68 
Data from the eligible studies were subsequently extracted by two authors (NA, AK) into a spreadsheet 69 
including information on the study characterises (study design, setting, sample size, population, exposure-70 
ACEIs/ARBs, ACEIs, or ARBs) and outcome measures including death, intensive care unit (ICU) 71 
admission, risk of COVID-19 infection, severe COVID-19 infection, severe pneumonia, hospitalisation, 72 
hospital discharge, use of ventilators, duration of hospital stay, septic shock, acute kidney injury, cardiac 73 
injury, and hospital readmission. Since the need for using ventilators typically necessitates ICU admission, 74 
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we combined studies that reported ICU admission and ventilator use as a further composite outcome 75 
measure. Two authors (NA and LA) independently conducted the assessment of risk of bias using the 76 
Newcastle-Ottawa Scale (NOS) for nonrandomised studies which consists of three domains (selection of 77 
participants and control (if applicable), comparability and exposure or outcome)  [32], whereby studies were 78 
classified into good quality (3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 79 
2 or 3 stars in outcome domain),  fair quality (2 stars in selection domain AND 1 or 2 stars in comparability 80 
domain AND 2 or 3 stars in outcome/exposure domain) and poor quality (0 or 1 star in selection domain 81 
OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain) [33]; any disagreement 82 
between the two reviewers (NA and LA) was resolved by involving a third researcher (AK) for discussion 83 
until a consensus was reached .Furthermore, interrater reliability measures such as kappa statistic and 84 
percentage agreement were also calculated. Some of the co-authors have used this approach before [34].  85 
 86 
Data Synthesis and Analysis 87 
For each study outcome that was reported by more than one study, the results from individual studies were 88 
combined statistically using the random-effects meta-analysis model, stratified by the level of exposure 89 
(ACEIs/ARBs, ACEIs, ARBs); whereas for outcomes which were reported by only one study, narrative 90 
synthesis was used. For studies which did not report the summary statistics and measure of effects, we 91 
firstly used the reported primary statistics (number of patients with/without the outcomes in both 92 
exposed/unexposed group) to calculate the corresponding measure of effects (Odds ratios- OR) and their 93 
95% confidence interval (95%CI) [35], and subsequently used these measure of effects in the random-94 
effects meta-analysis; random-effects model was used as it is considered the most appropriate model by 95 
most researchers since it allows the results to be generalisable to other populations as well as addresses 96 
the likely heterogeneity between the included studies [36]. Several sub-group analyses were also 97 
undertaken to explore the effect of potential confounders on the robustness and sensitivity of combined 98 
pooled estimates and included sub-group analyses based on whether the reported measure of effects was 99 
crude or adjusted, the study was peer-reviewed or not, the study’s methodological quality as per the risk of 100 
bias assessment was performed as well as the continent where the study was conducted. Meta-analyses 101 
pooled estimated were presented as odds ratios and 95%CI and graphically as forest plots. Heterogeneity 102 
between the studies was evaluated using I2 statistic [37], indicating whether variability is more likely due to 103 
study heterogeneity or chance. Negative I2 values were set to zero, hence I2 values ranged between 0%-104 
100% with 0% indicating lack of heterogeneity, whereas 25%, 50%, and 75% indicating low, moderate and 105 
high heterogeneity, respectively [37]. Publication bias was assessed using funnel plots and Egger’s 106 
asymmetry test [38] for those outcomes where >10 studies were included in the analysis as recommended 107 
by Cochrane guidelines [39]. Data were analysed using STATA 12. 108 
 109 
Role of the Funding Source 110 
None 111 
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Results 113 
Study characteristics  114 
The literature search identified 452 articles. However, only 27 studies were eligible for inclusion (Figure 1). 115 
A total of 72,372 patients were included in these 27 studies of which 10,197 (14.1%) patients were on 116 
ACEIs or ARBs. The average age of the population in these studies was 61±9.6 years and men represented 117 
52.24% of them (Table 1). Twenty-one studies (77.8%) focused on comparing COVID-19 related outcomes 118 
between ACEI/ARB users vs. non-users among patients with COVID-19 while the remaining six studies 119 
(22.2%) focused on comparing outcomes between ACEIs/ARBs users in patients with and without COVID-120 
19 infection (Table 1). ACEIs/ARBs in the included studies were indicated for a wide range of chronic 121 
conditions such as hypertension, coronary artery diseases, heart failure, diabetes or chronic kidney 122 
disease. 123 
 124 
In terms of outcomes, nine studies (33.3%) reported three to five COVID-19 related outcomes 125 
[20,23,25,26,40-44], while another nine studies (33.3%) reported only two outcomes [17,19,22,24,27,45-126 
48] with another one-third reported only one outcome [19,22,29,46-51].  Overall, the 27 studies reported 127 
data on 15 unique outcomes including death in 12 studies [18,21,28,49-54], ICU admission in seven studies 128 
[23,25,40-44], death/ICU admission as a composite outcome in four studies [21,40,45,54], risk of acquiring 129 
COVID-19 infection in nine studies [22,25,26,42-44,48,49,53], risk of severe COVID-19 infection in seven 130 
studies [17-19,22,24,48,50], risk of severe pneumonia in two studies [26,51], risk of hospitalisation in eight 131 
studies [26,42-47,52], hospital discharge in three studies [23,26,27], use of ventilator in four studies 132 
[19,23,41,44], duration of hospital stay in two studies [25,26], and each of acute respiratory distress 133 
syndrome (ARDS), septic shock, cardiac shock, acute kidney injury [20], and hospital readmission [23] in 134 
one study, respectively. In terms of the exposure, the effects of ACEIs and ARBs were assessed as one 135 
class (ACEIs/ARBs) in 17 studies (63%) [17,20,22-28,40,43,44,47,50,51,53,54], as separate classes in five 136 
studies (18.5%) 52, 74, 78, 80, 84), and both as one and separate classes in another five studies 137 
[18,19,41,45,49]. 138 
 139 
The majority of the 27 eligible studies were conducted in Asia (44.4%, n=12 with 10 studies from China, 140 
one from each of in Korea and Israel), followed by nine studies (33.3%) from Europe (four in Italy, three in 141 
the United Kingdom and one from each of France and Belgium) and the remaining six (22.3%) from the 142 
USA. Furthermore, the reported measure of effects were crude/un-adjusted measures in the majority of the 143 
studies (77.8%, n=21) [18,19,21-28,40-46,48,53,54]; with most of them (59.3%, n=16) being non-peer 144 
reviewed articles published as preprints on medRivix [24,26,27,40-43,45-48,50-54], and only four rated as 145 
a good quality studies based on the Newcastle-Ottawa Quality Assessment risk of bias [21,40,47,48] (Table 146 
2). Results from the interrater reliability measures indicated a substantial agreement between the two 147 
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independent reviewers (NA and LA) in assessing the risk of bias (kappa statistic=0.79; percentage of 148 
agreement=89% (24/27)).  149 
 150 
Study outcomes 151 
Death and ICU admission 152 
Among pertinent studies, there was insignificant association between mortality and ACEIs/ARBs (OR: 0.97; 153 
95%CI: 0.75 1.27), ACEIs (OR:1.05; 95%CI: 0.75, 1.46), or ARBs (OR:1.18, 95%CI: 0.98, 1.42) (Figure 2; 154 
Table 3), regardless of the studies’ country, quality, peer-review status or crude/adjusted measure of effect 155 
(Supplementary file 2; Table 4). Similarly, there was an insignificant association between ICU admission 156 
and ACEIs/ARBs (OR: 1.09; 95%: 0.65, 1.81) and ACEIs (OR:0.95; 95%CI: 0.65, 1.38) but significantly 157 
higher odds of ICU admission with ARBs (OR:1.49, 95%CI: 1.13, 1.97) (Figure 3; Table 3). However, sub-158 
group analyses indicated different results. A significantly lower ICU admission rate was associated with 159 
ACEIs/ARBs among European studies (OR:0.49; 95%CI: 0.25, 0.97), and good quality studies (OR:0.36; 160 
95%CI: 0.22, 0.59), in contrast to significantly higher ICU admission rate among USA studies (OR:1.59; 161 
95%CI: 1.28, 1.98), peer-reviewed studies (OR:1.56; 95%CI: 1.23, 1.97), and poor quality studies (OR:1.44; 162 
95%CI: 1.13, 1.84) (Supplementary file 3; Table 4). Meta-analysis of the three studies that reported death 163 
and ICU admission as a composite endpoint indicated  significantly lower odds of death/ICU admission with 164 
ACEIs/ARBs use (OR:0.67; 95%CI: 0.52, 0.86) but insignificant lower association with ACEIs (OR:0.89; 165 
95%CI: 0.69, 1.14) or ARBs (OR: 0.83; 95%CI: 0.65, 1.06), regardless of any sub-group analysis for ACEIs 166 
and ARBs (Figure 4; Table 3). The sub-group analyses for ACEIs/ARBs, however, showed a significantly 167 
lower association of death/ICU admission with ACEIs/ARBs only among European studies (OR: 0.68; 168 
95%CI: 0.52, 0.89), good quality studies (OR:0.63; 95%CI: 0.47, 0.84), and studies which reported adjusted 169 
measure of effect (OR:0.63; 95%CI: 0.47, 0.84) (Supplementary file 4; Table 4). 170 
 171 
Risk of acquiring COVID-19 infection, severe COVID-19 infection and severe pneumonia  172 
The overall pooled analysis of nine studies indicated insignificant association between the risk of acquiring 173 
COVID-19 infection and the use of ACEIs/ARBs (OR: 1.01; 95%CI: 0.93, 1.10), ACEIs (OR: 1.13; 95%CI: 174 
0.9, 1.42), or ARBs (OR: 0.56; 95%CI: 0.11, 2.89) (Figure 5; Table 3). The sub-group analyses results were 175 
consistent with overall analyses results for ACEIs/ARBs and ACEIs (Supplementary file 5A; Supplementary 176 
file 5B; Table 4) but there were inconsistent for ARBs with a significantly lower risk of acquiring COVID-19 177 
with ARBs among non-peer-reviewed studies, good quality studies and studies which reported crude 178 
measure of effects (OR: 0.24; 95%CI: 0.17, 0.34) (Supplementary file 5C; Table 4).  Similarly, in a pooled 179 
analysis of seven and two studies, insignificant association was observed between the risk of developing 180 
severe COVID-19 infection, severe pneumonia, respectively, and ACEIs/ARBs (OR:0.78; 95%CI: 0.53, 181 
1.15; OR:1.29; 95%CI: 0.24, 6.96), ACEIs (OR: 0.72; 95%CI: 0.26, 1.95) or ARBs (OR: 0.51; 95%CI: 0.25, 182 
1.04) (Figure 6; Table 3), regardless of any sub-group analysis (Supplementary file 6; Table 4).  183 
 184 
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Hospitalisation, hospital discharge and duration of hospital stay 185 
In a pooled analysis of eight and three studies, there was no signification association between 186 
hospitalisation, hospital discharge rate and ACEIs/ARBs (OR: 1.15; 95%CI: 0.81, 1.65; OR: 1.21; 95%CI: 187 
0.74, 1.99), ACEIs (OR: 1.08; 95%CI: 0.79, 1.46) or ARBs (OR: 0.91; 95%CI: 0.74, 1.11) (Figure 7; Figure 188 
8Table 3). However, sub-group analyses demonstrated a significantly higher risk of hospitalisation with 189 
ACEIs/ARBs among studies conducted in the USA (OR:1.59; 95%CI: 1.03, 2.44), peer-reviewed studies 190 
(OR:1.93, 95%CI: 1.38, 2.71), good quality studies and studies which reported adjusted measure of effect 191 
(OR:1.30, 95%CI: 1.10, 1.50) (Supplementary file 7; Table 4). Contrastingly, a significantly higher rate of 192 
hospital discharge was observed with ACEIs/ARBs but only among non-peer reviewed articles (OR:1.51; 193 
95%CI: 1.18, 1.93) (Supplementary file 8; Table 4). Two studies reported data on the duration of hospital 194 
stay. Both were in favour of ACEIs/ARBs with Yang G. et al [25] reporting a significant reduction in the 195 
mean duration of hospital stay of 2.3 days (95%CI: -3.61, -0.99) with ACEIs/ARBs whilst Zeng et al [26] 196 
reporting a lower median duration of hospital stay of 21 days (IRQ: 15-25) with ACEIs/ARBs versus 22 days 197 
(IQR: 16-28) with non-ACEI/ARB use.  198 
 199 
Use of a ventilator  200 
Among pertinent studies, there was no significant association between these outcomes and the use of 201 
ACEIs/ARBs (OR:1.49; 95%CI: 0.80, 2.77; OR: 1.26; 95%CI: 0.84, 1.80), ACEIs (OR:1.01; 95%CI:0.03, 202 
34.76; OR:1.15; 95%: 0.55, 2.38), or ARBs (OR:0.98; 95%CI: 0.08, 11.57; OR: 1.48; 95%CI: 0.91, 2.38) 203 
(Figure 9; Figure 10; Table 3). However, a significantly higher odds of ventilator use with ACEIs/ARBs 204 
among the European studies (OR: 3.34; 95%CI: 2.04, 5.48) and the USA (OR:1.52; 95%CI:1.17, 1.98) in 205 
contrast to significantly lower odds among those from Asia (OR:0.2; 95%CI: 0.04, 0.95) (Supplementary 206 
file 9, Table 4). Contrastingly, a significantly higher odds of ventilator use with ACEIs/ARBs was only 207 
observed among non-peer reviewed studies (OR:3.34; 95%CI: 2.04, 5.48) (Supplementary file 9, Table 1).  208 
 209 
Other miscellaneous outcomes 210 
Zhang et al [21] reported a significantly lower rate of septic shock (HR: 0.32; 95%CI: 0.13, 0.8) as well as 211 
non-significant lower rate of ARDS (HR: 0.65; 95%CI: 0.41, 1.04), acute kidney injury (HR:0.78; 95%CI: 212 
0.37, 1.65), and cardiac injury (HR: 0.76; 95%CI: 0.44, 1.32) among ACEI/ARB users. Furthermore, 213 
Richardson S. et al [24], reported lower odds of hospital readmission with ACEIs/ARBs (OR: 0.77; 95%CI: 214 
0.30, 1.94), albeit non-significant. 215 
 216 
Publication bias  217 
Results from the funnel plot (Supplementary file 10) and Egger’s asymmetry test for the death outcome, 218 
which was the only outcome whereby >10 studies were included in the meta-analysis, indicated statistically 219 
insignificant evidence of publication bias (bias coefficient:0.85, 95%CI: -2.23, 3.93, p=0.445).    220 
 221 
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Discussion 222 
The pooled analyses in this updated systematic review and meta-analysis indicated no evidence of any 223 
significant association between ACEIs/ARBs and any COVID-19 related clinical outcomes; however, the 224 
sub-group analyses revealed evidence of a negative impact of ACEIs/ARBs use and some COVID-19 225 
related clinical outcomes such as higher odds of hospitalisation, ICU admission and ventilator use. 226 
Contrastingly, a positive impact in terms of lower odds of death/ICU admission, as a composite outcome, 227 
and a higher rate of hospital discharge. Furthermore, our study findings, for the first time, showed inter-228 
class variations between ACEIs and ARBs effects on COVID-19 clinical outcomes with low quality evidence 229 
indicating lower risk of acquiring COVID-19, less severe COVID-19 infection, higher rate of ICU admission 230 
and ventilator use with ARBs but not ACEIs.  231 
 232 
Our study findings also showed no significant association between ACEIs/ARBs and mortality, severe 233 
COVID-19 infection, or positive tests for COVID-19, in agreement with two previously published systematic 234 
reviews [29,30]. This was despite the inclusion of more recently published studies [18,27,40,41,49,50,53], 235 
which implies consistency of evidence. This is encouraging given the controversies surrounding 236 
hydroxychloroquine.  Furthermore, these non-significant associations were also observed for additional 237 
COVID-19 related outcomes including ICU admission, hospitalisation, and hospital discharge. However, 238 
unlike the previous two systematic reviews [29,30], our study found evidence of associations between 239 
ACEI/ARB use and certain COVID-19 clinical outcomes. Whilst the pooled estimate of the sub-group 240 
analyses indicated a higher odds of ICU admission with ACEIs/ARBs among studies conducted in the USA 241 
[23,43,44] and peer-reviewed studies [23,25,44], all these studies were of poor quality and none performed 242 
adjusted analyses to account for potential confounders. Confounding by indication is of particular concern 243 
with comorbidities such as CVD and diabetes associated with more severe COVID-19 morbidity and 244 
mortality [4-6]. Similarly, the observed significant associations between ACEIs/ARBs use and high odds of 245 
ventilator use and hospital discharge rates were from Benelli et al [41] and Ip et al [27] and Zeng et al [26], 246 
respectively, all of which were non-peer reviewed, of poor quality and used crude analyses. Similarly, the 247 
studies in the pooled analyses that showed significant association of ARBs use and ICU admission [41,42], 248 
lower risk of acquiring COVID-19 infection [48], and severe infection [18,19] were of poor quality, used 249 
unadjusted/crude analyses, and/or non-peer reviewed. In terms of duration of hospital stay, Yang et al [25] 250 
and Zeng et al [26] both reported a reduction in hospital stay with ACEIs/ARBs; however, it was not possible 251 
to combine them in the meta-analysis as they used different measure of effects with the former reporting 252 
the outcome as a mean difference while the latter as a median.  253 
 254 
On the other hand, our study findings showed some high-quality evidence on the association of 255 
ACEIs/ARBs and higher odds of hospitalisation but lower odds of death/ICU admission (as a composite 256 
endpoint). The higher odd of hospitalisation was observed in the sub-group analyses of studies conducted 257 
in the USA [43,44] although it should be noted that there was some heterogeneity (57.7%) between the 258 
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USA studies, used adjusted analyses [47], peer-reviewed [44] and of good quality [47]; whereas the studies 259 
for lower death/ICU admission were from Europe [40,45], used adjusted analyses and of good quality [40], 260 
although none  of them were peer reviewed. 261 
 262 
Several hypotheses have been suggested to explain the negative and positive effects of ACEIs/ARBs use 263 
on COVID-19 clinical outcomes. The former is thought to be related to ACEIs/ARBs potential ability to up-264 
regulate ACE2, the cell entry point for COVID-19; hence facilitate COVID-19 cell entry and its subsequent 265 
infectivity/pathogenicity [55]; however, the evidence to date demonstrates ACE2’s up-regulation 266 
consistently in cardiac and renal tissues in response to ARBs therapy but not ACEIs [4,56]; this observed 267 
difference between ARBs and ACEIs has been suggested to be due to the increased level of angiotensin-268 
II, which occurs following ARBs treatment but not ACEIs, which in turn imposes an increased substrate 269 
load on ACE2 enzyme requiring its upregulation [57]. Importantly, it should be emphasised that evidence 270 
of ACEIs/ARBs induced ACE2 upregulation in the respiratory tracts, which is the key entry system for 271 
COVID-19, is lacking [56]. Furthermore, it should be noticed that alteration in angiotensin-II level, which is 272 
only one substrate of ACE2’s multiple substrates, is unlikely to result in any meaningful differences in ACE2 273 
substrate load, hence its upregulation [56]; additionally, the fact that people from various sexes, ages, and 274 
races are all susceptible to COVID-19 infection suggests that physiological expression of ACE2 might 275 
already be sufficient for COVID-19 infection; thus any further ACE2 upregulation might not have effects on 276 
the risk/severity of COVID-19 infection [25]. Together, these evidence indicate that the concerns around 277 
ACEIs/ARBs use in COVID-19 patients might be unjustifiable. On the other hand, the protective effect 278 
hypothesises on ACEIs/ARBs protecting against lung injury, through blockage of the harmful angiotensin 279 
II- AT1R axis, which gets activated by impairment of ACE2 activity as a result of ACE2’s downregulation 280 
results from ACE2’s binding with COVID-19 virus; additionally, the corresponding increase in  angiotensin 281 
II and angiotensin I, due to ACEIs/ARBs use, would activate the protective axis and hence reducing COVID-282 
19 viral pathogenicity [4]. Genetic ACE2 polymorphism among some individuals has been also suggested 283 
as potential factor explaining, at least partially, the harmful effects on ACEIs/ARBs among COVId-19 284 
patients [58]; but this needs further investigation. 285 
 286 
Strengths and limitation  287 
We believe this study is the first to provide a systematic, comprehensive and updated evaluation of the 288 
effects of ACEIs/ARBs on all the reported COVID-19 related clinical outcomes including exploration of inter-289 
class differences between ACEIs and ARBs as well as multiple sub-group analyses, although we do 290 
acknowledge that some of the sub-group analyses only had 1-2 studies for some of the studied outcomes 291 
such as ICU admission and Death/ICU admission. However, our study has limitations. Since all included 292 
studies were observational studies, the effect of confounding including residual confounders cannot be 293 
ruled out. There is also the possibility that new studies have been published since our review. However, we 294 
included non-peer reviewed articles published in medRxiv to help address this. 295 
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 296 
Conclusion    297 
There appears to be no evidence of association between ACEIs/ARBs use and a wide range of COVID-19 298 
related clinical outcomes. However, good quality evidence exists for ACEIs/ARBs and higher odds of 299 
hospitalisation, lower odds of death/ICU admission (as composite endpoint); but low-quality evidence for 300 
higher ICU admission, ventilator use, hospital discharge and lower duration of hospital stay. Furthermore, 301 
there are evidence, albeit of poor quality, of differences between ACEIs and ARBs with the latter being 302 
associated with significantly higher ICU admission but lower COVID-19 infection risk and severity. Given 303 
the continuing controversial and paradoxical clinical studies’ findings and hypotheses, we believe it is 304 
necessary to continue to evaluate the effects of ACEIs/ARBs on COVID-19 clinical outcomes especially as 305 
more randomised studies are reported. 306 
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Tables captions  
Table 1. Study characteristics  
 Population 
Total 
n 
Study 
Type 
Exposure 
n on 
RAAS 
inhibitors 
Outcome(s) 
Result (n or Odd Ratio + 
[95% confidence interval]) 
Bean D. et al 
(2020) [40]  
All adult 
symptomatic 
inpatient testing 
positive for 
COVID-19. 
1200 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
339 
• Death 
• Critical care admission 
• Death or critical care 
admission  
• n=106/399 vs. n=182/801 
• n= 21/399 vs. n=106/801 
• 0.63 (0.47-0.84) 
Benelli G. et 
al (2020) [41]  
Patients tested 
positive for 
COVID-19. 
411 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
110 
• Death 
• ICU admission 
• CPAP/NIV  
• n= 25/110 vs 47/301 
• n= 13/60 vs. 15/301 
•n= 42/110 vs. 70/301  
Bravi F. et al 
(2020) [45] 
Patients 
diagnosis of 
COVID-19.  
1603 
Case-
control 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
450 
• Severe or very 
sever/lethal  
• Very severe lethal  
• 0.58 (0.34-1.01) 
• 0.87 (0.50-1.49) 
Chodick G. et 
al (2020) [49]  
Patients with 
confirmed 
COVID-19.  
1317 Cohort 
ACEIs/ARBs 
users in patients 
with and without 
COVID-19 
132 
• Increased risk for 
COVID-19  
• 1.19 (0.96-1.47) 
Dauchet L. et 
al (2020) [42]* 
Patients aged 
35 years and 
over with 
suspected 
COVID-19.  
288 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
109 
• COVID-19+ 
• Hospitalisation  
• ICU admission  
Data reported for ACE 
inhibitor and ARBs 
separately  
DeSpiegeleer 
A. et al (2020) 
[50]  
All residents at 
two elderly care 
homes with 
confirmed 
COVID-19. 
154 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
30 • Serious COVID-19 • 0.48 (0.10-1.97) 
Feng Y. et al 
(2020) [19]  
Patients 
diagnosed with 
COVID-19. 
467 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
33 
Disease severity:  
• Moderate 
•Severe 
•Critical  
 
• n= 29/33 vs.319/443 
• n= 2/33 vs. 52/443 
• n= 2/33 vs. 68/443 
Feng Z. et al 
(2020) [51]  
All adult 
patients with 
564 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
16 Disease severity • 0.41 (0.05-3.19) 
 17 
confirmed 
COVID-19. 
among COVID-19 
patients  
Guo J. et al 
(2020) [28]  
Patients with 
COVID-19 
187 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
19 • Death • n=7/ 19 vs. n=36/168 
Ip Andrew et 
al (2020) [27]  
Patients 
hospitalized 
with confirmed 
COVID-19 
  
3017 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
NR 
• Death (expired) 
• Discharged  
•  1.6 [1.23-1.99] 
• n=323 vs. 407 
Khawaja A. et 
al (2020) [52]  
Patients 
hospitalized 
with COVID -19  
605 Cohort 
ACEIs/ARBs 
users in patients 
with and without 
COVID-19 
125 
• Hospitalisation with 
COVID-19 
Data reported for ACE 
inhibitor and ARBs 
separately 
Khera R. et al 
(2020) [46]  
Patients 
receiving anti-
hypertensive 
agents and 
tested positive 
for COVID-19. 
2263 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
852 
• Hospitalization 
• Mortality 
Data reported for ACE 
inhibitor and ARBs 
separately 
Li J. et al 
(2020) [24] 
Patients with 
COVID-19 and 
hypertension 
1178 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
115 
• Severity  
• Death  
• n=57/115 vs. 116/247 
• n=21/115 vs. 56/247 
Liu Y. et al 
(2020) [18]  
All patients 
were diagnosed 
with COVID-19 
and 
hypertension 
78 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
12 • Disease severity  
Data reported for ACE 
inhibitor and ARBs 
separately 
Mancia G. et 
al (2020) [21]  
Patients 40 
years of age or 
older with a 
Positive test of 
COVID -19 
6272 
Case-
control 
ACEIs/ARBs 
users in patients 
with and without 
COVID-19 
2896 
• Critical or fatal of 
clinical manifestations 
Data reported for ACE 
inhibitor and ARBs 
separately 
Mehta N. et al 
(2020) [44]  
Patients tested 
for COVID-19 
and had ACEI 
18472 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
212 
•  COVID-19+  
• Hospital admission 
• 0.97[0.81-1.15] 
• 1.93 (1.38-2.71) 
 18 
or ARB 
prescribed.  
among COVID-19 
patients  
• ICU-admission 
• Use of ventilator  
• 1.64 (1.07-2.51) 
• 1.32 (0.80-2.18) 
Meng J. el al 
(2020) [17]  
Patients with 
positive 
COVID-19. 
42 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
17 
• Hospitalisation  
• Hospital discharge 
• Severity of disease  
• Death 
• 4 days vs. 2 days  
• 20 days vs. 16.5 days  
• OR:0.33[0.09-1.31] 
• n=0/17 vs. n=1/25 
Raisi-
Estabragh Z.  
et al (2020) 
[53]  
Individuals 
tested for 
COVID-19 
aged 40-69 
years old.  
1474 Cohort 
ACEIs/ARBs 
users in patients 
with and without 
COVID-19 
312 COVID+ • 0.956[0.695-1.316] 
Rentsch Ch. 
et al (2020) 
[43]  
Veterans aged 
54-75 years 
with positive 
COVID-19 test 
585 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
255 
• COVID-19+ 
• Hospitalisation 
• ICU admission 
• 0.93[0.78-1.23] 
• 1.24[0.79-1.95] 
• 1.69[1.01-2.84]  
Reynolds H. 
et al (2020) 
[22] 
Patients who 
were tested for 
COVID-19. 
12594 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
2319 
• COVID-19+ 
• Severity of COVID-19 
• 1110/1909 vs. 1101/1909 
• 275/1110 vs. 274/1101 
Rhee S. et al 
(2020) [54]  
Patients with 
confirmed 
COVID-19 
832 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
327 •ICU admission or death  •  0.599[0.251-1.431]. 
Richardson S. 
et al (2020) 
[23]  
All patients who 
hospitalized 
with COVID-19 
infection. 
5700 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
413 
• Invasive mechanical 
ventilation 
• ICU care  
• Readmission  
• Discharged home 
• Death  
• n= 79/413 vs. n=122/953 
• n= 87/413 vs. 141/953  
• n=6/413 vs. n=18/953 
• n=261/413 vs. 639/953 
• n=130/413 vs. 254/953 
Rossi P. et al 
(2020) [47]  
All symptomatic 
patients who 
tested positive 
for COVID-19.  
2653 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
450 
• Death 
• Hospitalisation 
• 0.8[0.50-1.3] 
• 1.12 [0.82-1.54] 
Yan H. et al 
(2020) [48]  
Patients with 
confirmed 
diagnosis of 
COVID -19 
infection.  
610 
Case-
control 
ACEIs/ARBs 
users in patients 
with and without 
COVID-19 
NR 
• COVID-19+ 
• Disease severity of 
COVID-19 severe + 
critical vs. mild + 
common  
Data reported for ACE 
inhibitor and ARBs 
separately 
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Yang G. et al 
(2020) [25] 
Patients with 
confirmed 
COVID-19.  
462 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
43 
•Tested positive for 
COVID-19 
• Days patient remained 
in hospital (mean ±SD) 
• Critical severity 
• Death  
• n=43 vs. n=83  
• 35.2±12.8 vs. 37.5±12.3.  
• n=4 vs. n=19 
• n=2 vs. n=11  
Zeng Zh. et al 
(2020) [26]  
Adult patients 
with suspected 
and confirmed 
cases of 
COVID-19.  
274 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
28 
• Mortality  
• length of hospital stays 
(days) 
• discharge rate  
• hospitalization rate.  
• Tested positive for 
COVID 
• Severe pneumonia 
• n=2/28 vs. n=5/47 
• n=21(15.25) vs. n=22 (16-
28)  
• n=21/28 vs, n=29/47  
• n=5/28 vs. n=13/47  
• n=20/28 vs. n=31/47 
• n=15/28 vs. n=15/47 
Zhang P.et al 
(2020) [20] 
Patients 
diagnosed with 
COVID-19,  
1128 Cohort 
ACEIs/ARBs vs. 
non-ACEIs/ARBs 
among COVID-19 
patients  
188 
• Mortality 
• Acute respiratory 
distress syndrome  
• Septic shock  
• Acute kidney injury 
• Cardiac injury 
• 0.37 [0.15-0.89] 
• 0.65 [0.41-1.04] 
• 0.32 [0.13-0.80] 
• 0.78 [0.37-1.65] 
• 0.78 [0.44-1.32] 
(Note) *: this study reported data from two cohorts; hence it is included twice in the analyses; ACEIs: Angiotensin-converting-enzyme inhibitors; 
ARBs: Angiotensin II receptor blockers; COVID: coronavirus disease; CPAP: continuous positive airway pressure; ICU: intensive care unit; n: 
number of patients; NIV: non-invasive ventilation; NR: not reported; OR: odds ratio; RAAS: Renin-Angiotensin-Aldosterone System; SD: 
standard deviation 
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Table 2 Quality assessment score of the studies included into the systematic review and meta-analysis based on the using the Newcastle-
Ottawa Scale 
Cohort studies 
N Author (Month, year) Selection Comparability Outcome 
Final 
score 
Score 
Quality** 
1 Bean D. et al., (May 2020) [40] B* C A* A* Demographic* Comorbidities* B* A* C 7 Good 
2 Benelli G. et al., (April 2020) [41] B* C A* A* - - B* No C 4 Poor 
3 Chodick G. et al., (May 2020) [49] B* C A* A* Demographic* Comorbidities* B* NA D 6 Poor 
4 DeSpiegeleer A. et al., (May 2020) [50] B* C A* A* Demographic* Comorbidities* B* NA D 6 Poor 
5 Feng Y. et al., (April 2020) [19] B* C A* A* - - B* NA D 4 Poor 
6 Feng Z. et al., (April 2020) [51] B* C A* A* - - B* NA D 4 Poor 
7 Khawaja A. et al., (May 2020) [52] A* A* A* A* Demographic* Comorbidities* B* NA D 7 Poor 
8 Khera R. et al., (2020) [46] B* A* A* A* - - B* NA D 5 Poor 
9 Li J. et al., (April 2020) [24] B* C A* A* - - B* NA D 4 Poor 
10 Dauchet L. et al., (May 2020) [42] B* A* A* A* - - B* NA D 5 Poor 
11 Ip Andrew et al., (April 2020) [27] B* C A* A* - - B* NA D 4 Poor 
12 Liu Y. et al., (March 2020) [18] A* C A* A* - - B* NA D 4 Poor 
13 Mehta N. et al., (May 2020) [44] A* A* A* A* - - B* NA D 5 Poor 
14 Raisi-Estabragh Z. et al., May 2020) [53] B* A* A* A* - - B*     5 Poor 
15 Rhee S. et al., (May 2020) [54] A* A* A* A* Demographic* Comorbidities* B* NA D 7 Poor 
16 Yang G. et al., (May 2020) [25] B* A* A* A* - - B* B D 5 Poor 
17 Zeng Zh.et al., (April 2020) [26] B* A* A* A* - - B* A* A* 7 Poor 
18 Zhang P. et al., (April 2020) [20] A* A* A* A* Demographic* Comorbidities* B* NA D 7 Poor 
19 Rossi P. et al., (April 2020) [47] A* C A* A* Demographic* Comorbidities* B* A* A* 8 Good 
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20 Reynolds H. et al., (May 2020) [22] B* A* A* A* Demographic* Comorbidities* B* NA D 7 Poor 
21 Rentsch Ch. et al., (April 2020) [43] B* C A* A* - - B* NA D 4 Poor 
22 Meng J. el al., (March 2020) [17] B* C A* A* - - B* NA D 4 Poor 
23 Guo J. et al., (May 2020) [28] A* C A* A* - - B* NA D 4 Poor 
24 Richardson S. et al., (April 2020) [23] A* C A* A* - - B* B D 4 Poor 
Case-control studies 
25 Bravi F. et al., (May 2020) [45] A* A* A* A* - - A* A* C 6 Poor 
26 Mancia G. et al., (May 2020) [21] A* A* A* A* - 
Comorbidities 
* 
A* A* C 7 Good 
27 Yan H. et al., (April 2020) [48] A* A* A* A* Demographic* - B* A* D 6 Good 
(Note) **Studies were classified into good quality (3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in 
outcome domain), fair quality (2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain) 
and poor quality (0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain) (33) 
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Table 3. Meta-analyses pooled estimates with 95%CI of the effects of ACEIs/ARBs on COVID-19 related clinical outcomes 
 
Outcomes  ACEIs/ARBs p-value ACEIs p-value ARBs P-value 
Death  0.973 (0.746, 1.269) 0.84 1.049 (0.751, 1.464) 0.781 1.181 (0.983, 1.418) 0.076 
Number of studies  11  2  2  
I-squared 65.5%  0.001 26.3% 0.244 0.6% 0.316 
ICU 1.086 (0.652, 1.809) 0.75 0.945 (0.65, 1.376) 0.769 1.49 (1.126, 1.973) 0.005 
Number of studies  6  3  3  
I-squared (p-value) 84.4% <0.001 4.9% 0.349 0% 0.475 
Death/ICU 0.67 (0.524, 0.857) 0.001 0.888 (0.694, 1.136) 0.345 0.83 (0.65, 1.061) 0.136 
Number of studies  3  2  2  
I-squared (p-value) 0% 0.572 0% 0.726 0% 1.000 
Risk of COVID-19 1.014 (0.935, 1.099) 0.745 1.133 (1.417, 21.27) 0.273 0.557 (0.107, 2.895) 0.46 
Number of studies  7  3  2  
I-squared (p-value) 0% 0.75 0% 0.457 97.9% <0.001 
Severe COVID-19 0.782 (0.529, 1.154) 0.215 0.718 (0.264, 1.955) 0.517 0.506 (0.247, 1.036) 0.062 
Number of studies  6  3  3  
I-squared (p-value) 43.3% 0.117 0% 0.799 18% 0.296 
Severe pneumonia  1.285 (0.237, 6.958) 0.771 NA  NA  
Number of studies  2      
I-squared (p-value) 57.5% 0.125     
Hospitalisation  1.153 (0.806, 1.65) 0.436 1.077 (0.791, 1.465) 0.638 0.907 (0.74, 1.112) 0.349 
Number of studies  5  5  5  
I-squared (p-value) 74.5% 0.003 63.7% 0.026 0% 0.965 
Hospital discharge  1.213 (0.739, 1.991) 0.446 NA  NA  
Number of studies  3      
I-squared (p-value) 82.2% 0.004     
Ventilator use  1.492 (0.804, 2.77) 0.205 1.014 (0.03, 34.758) 0.994 0.985 (0.084, 11.57) 0.990 
Number of studies  4  2  2  
I-squared (p-value) 80.7% 0.001 64.7% 0.092 88.6% 0.003 
ICU/ventilator use 1.225 (0.836, 1.795) 0.298 1.149 (0.554, 2.382) 0.709 1.467 (0.907, 2.373) 0.118 
Number of studies  10  5  5  
I-squared (p-value) 83.2% <0.001 75.2% 0.003 66.2% <0.001 
(Note) NA: not applicable indicating no enough studies to perform meta-analyses 
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Table 4. Sub-group meta-analyses pooled estimates with 95%CI of the effects of ACEIs/ARBs on COVID-19 related clinical outcomes 
 Death (n=15) 
ACEIs/ARBs ACEIs ARBs  
Adjusted outcome measure    
Adjusted OR 0.973 (0.260, 1.660) NA NA 
Crude OR 1.048 (0.772, 1.424) 1.049 (0.751, 1.464)* 1.181 (0.983, 1.418)* 
Number of studies  2 vs 9 0 vs. 2 0 vs. 2 
Peer reviewed article?     
Yes 0.894 (0.522, 1.533) NA NA 
No 1.004 (0.716, 1.408) 1.049 (0.751, 1.464)* 1.181 (0.983, 1.418)* 
Number of studies  6 vs. 5 0 vs. 2 0 vs. 2 
Study’s quality     
Good quality  1.113 (0.884, 1.400) NA NA 
Poor quality  0.915 (0.627, 1.336) 1.049 (0.751,1.464)* 1.181 (0.983,1.418)* 
Number of studies  2 vs. 9 0 vs. 2 0 vs. 2 
Study’s country     
Europe  1.176 (0.932, 1.483) 1.523 (0.728, 3.185) 1.645 (0.838, 3.229) 
USA 0.92 (0.494, 1.714) 0.97 (0.811, 1.161) 1.15 (0.954, 1.386) 
Asia 0.753 (0.401, 1.413) NA NA 
Number of studies  3 vs. 2 vs. 6 1 vs. 1 vs. 0 1 vs. 1 vs. 0 
 ICU admission (n=12) 
Adjusted outcome measure    
Adjusted OR NA NA NA 
Crude OR 1.086 (0.652, 1.809)* 0.945 (0.650, 1.376)* 1.490 (1.126, 1.973)* 
Number of studies  0 vs. 6 0 vs. 3 0 vs. 3 
Peer reviewed article?     
Yes 1.560 (1.234, 1.972) NA NA 
No 0.762 (0.295, 1.972) 0.945 (0.650, 1.376)* 1.490 (1.126, 1.973)* 
Number of studies  3 vs. 3 0 vs. 3 0 vs. 3 
Study’s quality     
Good quality  0.364 (0.224, 0.591) NA NA 
Poor quality  1.445 (0.133, 1.843) 0.945 (0.650, 1.376)* 1.490 (1.126, 1.973)* 
Number of studies  1 vs. 5 0 vs. 3 0 vs. 3 
Study’s country     
Europe  0.495 (0.253, 0.966) 0.945 (0.650, 1.376)* 1.490 (1.126, 1.973)* 
USA 1.591 (1.277, 1.983) NA NA 
Asia 1.439 (0.600, 3.453) NA NA 
Number of studies  2 vs. 3. vs. 1 3 vs. 0. vs. 0 3 vs. 0. vs. 0 
 Death/ICU admission (n=7) 
Adjusted outcome measure    
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Adjusted OR 0.630 (0.471, 0.842) NA NA 
Crude OR 0.783 (0.493, 1.243) 0.888 (0.694, 1.136)* 0.830 (0.650, 1.061)* 
Number of studies  1 vs. 2 0 vs. 2 0 vs. 2 
Peer reviewed article?     
Yes NA 0.910 (0.690, 1.210) 0.830 (0.630, 1.100) 
No 0.670 (0.524, 0.857)* 0.820 (0.490, 1.360) 0.830 (0.500, 1.400) 
Number of studies  0 vs. 3 1 vs. 1 1 vs. 1 
Study’s quality     
Good quality  0.630 (0.471, 0.842) 0.910 (0.687, 1.205) 0.830 (0.628, 1.097) 
Poor quality  0.783 (0.493, 1.243) 0.820 (0.492, 1.366) 0.830 (0.496, 1.389) 
Number of studies  1 vs. 2 1 vs. 1 1 vs. 1 
Study’s country     
Europe  0.679 (0.520, 0.887) 0.888 (0.694, 1.136) 0.830 (0.650, 1.061) 
USA NA NA NA 
Asia 0.599 (0.251, 1.430) NA NA 
Number of studies  2 vs. 0 vs. 1 2 vs. 0 vs. 0 2 vs. 0 vs. 0 
 Risk of COVID-19 infection (n=12) 
Adjusted outcome measure    
Adjusted OR 1.190 (0.962, 1.473) 1.180 (0.867, 1.605) 1.290 (0.930, 1.790) 
Crude OR 0.986 (0.904, 1.077) 1.015 (0.620, 1.662) 0.240 (0.170, 0.340) 
Number of studies  1 vs. 6 1 vs. 2 1 vs. 1 
Peer reviewed article?     
Yes 1.030 (0.941, 1.128) 1.180 (0.867, 1.605) 1.290 (0.930, 1.790) 
No 0.948 (0.790, 1.138) 1.015 (0.620, 1.662) 0.240 (0.170, 0.340) 
Number of studies  4 vs. 3 1 vs. 2 1 vs. 1 
Study’s quality     
Good quality  NA 0.650 (0.265, 1.597) 0.240 (0.170, 0.339) 
Poor quality  1.014 (0.935, 1.099)* 1.176 (0.933, 1.481) 1.290 (0.930, 1.790) 
Number of studies  0 vs. 7 1 vs. 2 1 vs. 1 
Study’s country     
Europe  0.956 (0.695, 1.316) 1.170 (0.825, 1.660) NA 
USA 0.99 (0.901, 1.087) NA NA 
Asia 1.131 (0.942, 1.358) 1.023 (0.622, 1.684) 0.557 (0.107, 2.895)* 
Number of studies  1 vs. 3 vs. 3 1 vs. 0 vs. 2 0 vs. 0 vs. 2 
 Severe COVID-19 (n=12) 
Adjusted outcome measure    
Adjusted OR 0.480 (0.108, 2.130) NA NA 
Crude OR 0.795 (0.525, 1.206) 0.718 (0.264, 1.955)* 0.506 (0.247, 1.036)* 
Number of studies  1 vs. 5 0 vs. 3 0 vs. 3 
Peer reviewed article?     
Yes 0.895 (0.614, 1.303) 0.595 (0.067, 5.296) 0.333 (0.069, 1.607) 
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No 0.387 (0.144, 1.040) 0.755 (0.245, 2.328) 0.509 (0.176, 1.474) 
Number of studies  4 vs. 2 1 vs, 2 1 vs. 2 
Study’s quality     
Good quality  NA 1.230 (0.190, 7.946) 0.770 (0.362, 1.638) 
Poor quality  0.782 (0.529, 1.154)* 0.578 (0.176, 1.893) 0.283 (0.101, 0.792) 
Number of studies  0 vs. 6 1 vs. 2 1 vs. 2 
Study’s country     
Europe  0.480 (0.108, 1.130) NA NA 
USA 0.994 (0.820, 1.205) NA NA 
Asia 0.513 (0.216, 1.216) 0.718 (0.264, 1.955)* 0.506 (0.247, 1.036)* 
Number of studies  1 vs. 1 vs. 4 0 vs. 0 vs. 3 0 vs. 0 vs. 3 
 Severe pneumonia (n=2) 
Adjusted outcome measure    
Adjusted OR 0.410 (0.050, 3.275) NA NA 
Crude OR 2.462 (0.939, 6.452) NA NA 
Number of studies  1 vs. 1   
Peer reviewed article?     
Yes NA NA NA 
No 1.285 (0.237, 6.958) NA NA 
Number of studies  0 vs. 2   
Study’s quality     
Good quality  NA NA NA 
Poor quality  1.285 (0.237, 6.958) NA NA 
Number of studies  0 vs. 2   
Study’s country     
Europe  NA NA NA 
USA NA NA NA 
Asia 1.285 (0.237, 6.958)   
Number of studies  0 vs. 0 vs. 2   
 Hospitalisation (n=15) 
Adjusted outcome measure    
Adjusted OR 1.300 (1.113, 1.518) 1.170 (0.900, 1.520) 1.0 (0.702, 1.424) 
Crude OR 1.032 (0.561, 1.897) 1.056 (0.684, 1.631) 0.865 (0.674, 1.109) 
Number of studies  1 vs. 4 1 vs. 4 1 vs. 4 
Peer reviewed article?     
Yes 1.930 (1.377, 2.705) NA NA 
No 0.977 (0.647, 1.474) 1.077 (0.791, 1.465)* 0.907 (0.740, 1.112)* 
Number of studies  1 vs. 4 0 vs. 5 0 vs. 5 
Study’s quality     
Good quality  1.300 (1.113, 1.518) NA  NA 
Poor quality  1.032 (0.561, 1.897) 1.077 (0.791, 1.465)* 0.907 (0.740, 1.112)* 
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Number of studies  1 vs. 4 0 vs. 5 0 vs. 5 
Study’s country     
Europe  0.907 (0.413, 1.992) 1.181 (0.843, 1.656) 0.922 (0.721, 1.179) 
USA 1.589 (1.033, 2.443) 0.77 (0.527, 1.124) 0.877 (0.611, 1.258) 
Asia 0.569 (0.178, 1.815) NA NA 
Number of studies  2 vs. 2 vs. 1 4 vs. 1 vs. 0 4 vs. 1 vs. 0 
 Hospital discharge (n=3) 
Adjusted outcome measure    
Adjusted OR NA NA  NA  
Crude OR 1.213 (0.739, 1.991) NA  NA  
Number of studies  0 vs. 3   
Peer reviewed article?     
Yes 0.844 (0.663, 1.074) NA  NA  
No 1.513 (1.184, 1.935) NA  NA  
Number of studies  1 vs. 2   
Study’s quality     
Good quality  NA NA  NA  
Poor quality  1.213 (0.739, 1.991) NA  NA  
Number of studies  0 vs. 3   
Study’s country     
Europe  NA NA NA 
USA 1.122 (0.641, 1.964) NA NA 
Asia 1.862 (0.659, 5.26) NA NA 
Number of studies  0 vs. 2 vs. 1   
 Ventilator use (n=8) 
Adjusted outcome measure    
Adjusted OR NA NA NA 
Crude OR 1.492 (0.804, 2.770) 1.014 (0.03, 34.758) 0.985 (0.084, 11.57) 
Number of studies  0 vs. 4 0 vs. 2 0 vs. 2 
Peer reviewed article?     
Yes 1.141 (0.606, 2.150) 0.078 (0.001, 6.878) 0.251 (0.053, 1.185) 
No 3.338 (2.035, 5.475) 3.603 (1.889, 6.872) 3.129 (1.699, 5.761) 
Number of studies  1 vs. 3 1 vs. 1 1 vs. 1 
Study’s quality     
Good quality  NA NA NA 
Poor quality  1.492 (0.804, 2.770) 1.014 (0.030, 34.758) 0.985 (0.084, 11.570) 
Number of studies  0 vs. 4 0 vs. 2 0 vs. 2 
Study’s country     
Europe  3.338 (2.035, 5.475) 3.603 (1.889, 6.872) 3.129 (1.699, 5.762) 
USA 1.524 (1.171, 1.985) NA NA 
Asia 0.202 (0.043, 0.947) 0.078 (0.001, 6.469) 0.251 (0.053, 1.187) 
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Number of studies  1 vs. 2 vs. 1 1 vs. 0 vs. 1 1 vs. 0 vs. 1 
(Note) *Indicates that the pooled estimate is the same as the overall analyses because all the studies were in one group; NA: not applicable 
indicating that no studies were available to perform meta-analyses for these outcomes;  
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Figures captions 
 
 Figure 1 Study selection 
 
 
Figure 2 Forest plot depicting pooled estimates for the association between mortality and the three level of 
renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 3 Forest plot depicting pooled estimates for the association between Intensive Care Unit admission 
and the three level of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 4 Forest plot depicting pooled estimates for the association between the composite outcome of 
mortality/ Intensive Care admission and the three level of renin-angiotensin system drug exposure 
(ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 5 Forest plot depicting pooled estimates for the association between risk of acquiring COVID-19 
infection and the three level of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 6 Forest plot depicting pooled estimates for the association between developing severe COVID-19 
infection and the three level of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 7 Forest plot depicting pooled estimates for the association between hospitalisation and the three level 
of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 8 Forest plot depicting pooled estimate for the association between hospital discharge and 
ACEIs/ARBs use 
 
Figure 9 Forest plot depicting pooled estimates for the association between use of ventilator and the three 
level of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
 
Figure 10 Forest plot depicting pooled estimates for the association between use of ventilator/Intensive Care 
Unit admission and the three level of renin-angiotensin system drug exposure (ACEIs/ARBs, ACEIs, ARBs) 
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Supplementary files’ captions and legends 
  
Supplementary file 1. Search strategy used in the database searches 
 
Supplementary file 2. Forest plot depicting sub-group analyses pooled estimates for the association between 
mortality and ACEIs/ARBs use sub-grouped by A) country; B) methodological quality; C) peer-review status; 
and D) type of analyses (crude vs. adjusted) 
 
Supplementary file 3.  Forest plot depicting sub-group analyses pooled estimates for the association between 
Intensive Care Unit admission and ACEIs/ARBs use sub-grouped by A) country; B) methodological quality; 
C) peer-review status 
 
Supplementary file 4. Forest plot depicting sub-group analyses pooled estimates for the association between 
the composite outcome of mortality/ Intensive Care admission and ACEIs/ARBs use sub-grouped by A) 
country; B) methodological quality; C) type of analyses (crude vs. adjusted) 
 
Supplementary file 5A. Forest plot depicting sub-group analyses pooled estimates for the association 
between risk of acquiring COVID-19 infection and ACEIs/ARBs use sub-grouped by A) country; B) peer-
review status; and C) type of analyses (crude vs. adjusted) 
 
Supplementary 5B. Forest plot depicting sub-group analyses pooled estimates for the association between 
risk of acquiring COVID-19 infection and ACEIs use sub-grouped by A) country; B) methodological quality; 
C) peer-review status; and D) type of analyses (crude vs. adjusted) 
 
Supplementary 5C. Forest plot depicting sub-group analyses pooled estimates for the association between 
risk of acquiring COVID-19 infection and ARBs use sub-grouped by A) methodological quality; B) peer-review 
status; and C) type of analyses (crude vs. adjusted) 
 
Supplementary file 6. Forest plot depicting sub-group analyses pooled estimates for the association between 
developing severe COVID-19 infection and ACEIs/ARBs use sub-grouped by A) country; B) peer-review 
status; and C) type of analyses (crude vs. adjusted) 
 
Supplementary file 7. Forest plot depicting sub-group analyses pooled estimates for the association between 
hospitalisation and ACEIs/ARBs use sub-grouped by A) country; B) methodological quality; C) peer-review 
status; and D) type of analyses (crude vs. adjusted) 
 
Supplementary file 8. Forest plot depicting sub-group analyses pooled estimates for the association between 
hospital discharge and ACEIs/ARBs use sub-grouped by A) country; B) peer-review status 
 
Supplementary file 9. Forest plot depicting sub-group analyses pooled estimates for the association between 
ventilator use and ACEIs/ARBs use sub-grouped by A) country; B) peer-review status 
 
Supplementary file 10. Publication bias funnel plot for studies evaluated death outcome  
 
